LGND

Ligand Pharmaceuticals Incorporated

LGND, USA

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

https://www.ligand.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
LGND
stock
LGND

Stifel Nicolaus Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Defense World

Read more →
LGND
stock
LGND

Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $235.00 at Royal Bank Of Canada Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$237.5

Analyst Picks

Strong Buy

4

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

89.11

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

3.95

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Low

12.34 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

High

7.94 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

High

11.39 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

High

0.55

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 115.16% of the total shares of Ligand Pharmaceuticals Incorporated

1.

BlackRock Inc

(14.9465%)

since

2025/06/30

2.

Vanguard Group Inc

(10.7177%)

since

2025/06/30

3.

iShares Core S&P Small-Cap ETF

(5.8855%)

since

2025/08/31

4.

HHG PLC

(5.4412%)

since

2025/06/30

5.

Macquarie Group Ltd

(4.7529%)

since

2025/06/30

6.

State Street Corp

(3.846%)

since

2025/06/30

7.

Dimensional Fund Advisors, Inc.

(3.6139%)

since

2025/06/30

8.

Macquarie Small Cap Core I

(3.4388%)

since

2025/07/31

9.

Congress Asset Management Company, LLP

(3.3237%)

since

2025/06/30

10.

Stephens Inv Mgmt Group LLC

(3.1025%)

since

2025/06/30

11.

Janus Henderson Triton D

(3.0615%)

since

2025/06/30

12.

Janus Henderson US SMID Cap Growth

(3.0615%)

since

2025/06/30

13.

Janus Henderson US SMID Cap Growth MA

(3.0615%)

since

2025/06/30

14.

Vanguard Total Stock Mkt Idx Inv

(2.9473%)

since

2025/07/31

15.

Chicago Capital LLC

(2.9333%)

since

2025/06/30

16.

Geode Capital Management, LLC

(2.5073%)

since

2025/06/30

17.

iShares Russell 2000 ETF

(2.3667%)

since

2025/08/31

18.

Vanguard Small Cap Index

(2.2822%)

since

2025/07/31

19.

Loomis, Sayles & Company LP

(2.1078%)

since

2025/06/30

20.

Stephens SMID Select Growth

(2.1051%)

since

2025/06/30

21.

UBS Asset Mgmt Americas Inc

(2.0097%)

since

2025/06/30

22.

Congress Small Cap Growth Institutional

(1.7954%)

since

2025/07/31

23.

Massachusetts Financial Services Company

(1.7428%)

since

2025/06/30

24.

Rice Hall James & Associates, LLC

(1.7305%)

since

2025/06/30

25.

Vanguard Explorer Inv

(1.6115%)

since

2025/06/30

26.

Deutsche Bank AG

(1.5789%)

since

2025/06/30

27.

Ashford Capital Management Inc

(1.5519%)

since

2025/06/30

28.

Ranger Investment Management LP

(1.539%)

since

2025/06/30

29.

Villere St Denis J & Co Llc

(1.4728%)

since

2025/06/30

30.

Vanguard Small Cap Value Index Inv

(1.4705%)

since

2025/07/31

31.

Janus Henderson Venture D

(1.467%)

since

2025/06/30

32.

Janus Henderson US Small Cap Growth

(1.467%)

since

2025/06/30

33.

Northern Trust Corp

(1.4198%)

since

2025/06/30

34.

Impax Asset Management Group PLC

(1.3348%)

since

2025/06/30

35.

DWS Small Cap Core S

(1.3337%)

since

2025/07/31

36.

Small Cap Core Equity Composite

(1.3337%)

since

2025/07/31

37.

Impax Small Cap Institutional

(1.2322%)

since

2025/07/31

38.

Impax US Small Cap Strategy Composite

(1.2322%)

since

2025/07/31

39.

MFS New Discovery I

(1.1769%)

since

2025/07/31

40.

Loomis Sayles Small Cap Growth Instl

(1.1587%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

2.05

Latest Release

Date

2025-09-30

EPS Actual

3.09

EPS Estimate

1.93

EPS Difference

1.16

Surprise Percent

60.1036%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(8.5)
GARP
Strong GARP(8.5)
Growth
High Growth(7)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(8.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.